AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03495921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Injectable formulation of irinotecan was distributed from central supplier. 1 Cycle (5 doses of 50 mg/m2 per syringe) was drawn into provided oral syringes and dispenses to the subject with instructions to refrigerate until administration.
Study NCT03495921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Dose: 100 mg/m2 daily, oral Schedule: Days 1-5, every 21 days Administered at least 1 hour before Irinotecan.
Study NCT03855800 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pancreatic Surgery
Description: Surgical resection of pancreatic cyst
Study NCT03855800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy Exam
Description: Clinically indicated endoscopic ultrasound
Study NCT01274611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Botox will be injected into the underarm, targeting the sweat glands, to stop underarm sweating.
Study NCT01274611 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction-Curettage
Description: The doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. It is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located to decrease underarm sweating.
Study NCT00846716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone add on to SU or biguanide
Description: As an initial dosing, 15mg/day of pioglitazone is administered to the patients for 2 years, who are taking SU or biguanide.
Study NCT00846716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SU or Biguanide
Description: As an initial dose,a common dose of SU or biguanide is administered to the patients for 2 years.
Study NCT02320344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partners in Care
Description: The diabetes self-management intervention is titled, Partners in Care, emphasizing that there are many individuals and groups that one can call upon to assist with managing one's diabetes. The content includes practical behavioral strategies to improve diabetes self-management practices. The 12 week curriculum provides a basic overview of diabetes and self-management activities, standards of care recommended by the American Diabetes Association, strategies to improve patient-provider communication, support needed for diabetes self-management, information about diabetes medications, and ways to avoid diabetes-related complications.
Study NCT01335529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir, Peg-interferon alfa 2b and Ribavirin
Description: * Screen period from Week-8~* Standard treatment from day 0 to week 4 (W4)~* Three-drug-regimen (Boceprevir introduction) from W4 to W8~* HCV RNA determination at W8 determines treatment group and participation duration:~  * If undetectable HCV RNA at W8, it is a complete virological response: 3 drug-regimen is continued until W48, then there is a follow-up period up to W72 and SVR analysis,~ * If HCV RNA ≤ 1000IU/mL at W8, it is an incomplete virological response. The 3-drug-regimen is continued until W72, when another analysis is done.
Study NCT02290938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MICUNAY
Description: MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
Study NCT02290938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Wellness Gathering
Description: a monthly gathering focused on making healthy choices and learning about Native American culture
Study NCT00906269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil therapy plus post-NSRRP HBO2T
Description: Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
Study NCT00906269 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sildenafil therapy plus sham post-NSRRP HBO2T
Description: Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
Study NCT03159104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenoten for children
Description: Tablet for oral use.
Study NCT03159104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral use.
Study NCT01638559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppression withdrawal
Description: Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
Study NCT01739543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hem-Avert
Description: Application of Hem-Avert
Study NCT02741037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic lifestyle intervention
Description: Dyadic lifestyle intervention: The dyadic behavioral lifestyle intervention was modeled after the Diabetes Prevention Program (DPP), and was adapted to make it more easily accessible to low-income Latinas. In addition, this intervention arm has a dyadic component to examine the effectiveness of mothers and daughters engaging in the lifestyle intervention together as partners. Participants also will receive usual care.
Study NCT02741037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual lifestyle intervention
Description: Individual lifestyle intervention: The individual behavioral lifestyle intervention was modeled after the Diabetes Prevention Program, and was adapted to make it more easily accessible to low-income Latinas. Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers. Participants also will receive usual care.
Study NCT02741037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care: Mother and daughter participants will receive Usual Care.
Study NCT02741037 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual Care: Mother and daughter participants will receive Usual Care.
Study NCT03052530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapphire II PRO
Description: To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.
Study NCT02410577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-J591
Description: The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.
Study NCT02410577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT Scan
Study NCT02410577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT02410577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.
Study NCT02212158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing group
Description: Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.
Study NCT01908439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole-body vibration
Description: High amplitude whole-body vibration
Study NCT02881528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Liquid formula metformin administered by oral syringe in a dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
Study NCT02881528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid formula of placebo administered by oral syringe in an equivalent volume to a metformin dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
Study NCT04141189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: weekly
Description: fetal surveillance frequency
Study NCT04141189 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bi-weekly
Description: fetal surveillance frequency
Study NCT01662193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 supplement
Study NCT01662193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium supplement
Study NCT01662193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 and calcium supplement
Study NCT04700891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Edmonton Frail Scale
Description: The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
Study NCT03495921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Dose: 100 mg/m2 daily, oral Schedule: Days 1-5, every 21 days Administered at least 1 hour before Irinotecan.
Study NCT01039233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet
Study NCT04700891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Handgrip strength
Description: Handgrip strength is a simple and reliable measurement technique for the assessment of maximal voluntary hand force. Handgrip strength is used as a reflect of nutritional status and muscle mass, physical function and health status. Measurement will be realized using a digital handgrip dynamometer. Patients will be asked to grip the dynamometer with the second finger node at 90° angle to the handle and to grab the handle as strongly as they can. Maximal grip strength will be checked with the forearm away from the body in standing position.
Study NCT01039233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet
Study NCT01085357 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract Surgery
Description: Cataract Surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
Study NCT01085357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Cataract Surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
Study NCT01085357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPass Micro-Stent
Description: The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye after completion of cataract surgery.
Study NCT03519347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potassium Removal Maximization
Description: This intervention will test whether prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia reduces the incidence of clinically significant arrhythmias compared to an approach minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
Study NCT03519347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potassium Gradient Minimization
Description: This intervention will test whether minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients reduces the incidence of clinically significant arrhythmias compared to an approach prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
Study NCT01851330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
Study NCT01662193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02476929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal nitrous oxide
Description: Electrochemical device (NOVario Analizer FILT), to determine reference values of Nasal nitrous oxide.
Study NCT01851330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT04221230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTRX-335140
Description: Active Drug
Study NCT03519347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alkalosis Avoidance
Description: The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing alkalosis avoidance by use of lower dialysate HCO3 concentrations.
Study NCT03519347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acidosis avoidance
Description: The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing acidosis avoidance by use of higher dialysate HCO3 concentrations.
Study NCT03946592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Inject the Drug into submental fat via subcutaneous
Study NCT03946592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ211
Description: Inject the Drug into submental fat via subcutaneous
Study NCT04093544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Steered stimulation using directional leads
Study NCT04221230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04272424 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic mesh fixation
Description: laparoscopic mesh fixation by non fixation,tacker and histoacryl
Study NCT02012426 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight management program
Study NCT04093544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Steered stimulation using directional leads
Study NCT02012426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight management program
Study NCT00695058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)
Description: A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum in women and the perineum or the frenulum in men.~In the women the stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz. In the men the vibration parameter/location will be determined by the results of the new pressure profile studies (aim 3).~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks in both the women with stress incontinence and overactive bladder syndrome.~In the 3 groups of patients the subjects will be randomized to either active treatment or placebo treatment. The placebo treatment will be done with a vibration device with an amplitude of 0 mm. Subjects will be randomized by a draw.
Study NCT00695058 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)
Description: A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum in women and the perineum or the frenulum in men.~In the women the stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz. In the men the vibration parameter/location will be determined by the results of the new pressure profile studies (aim 3).~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks in both the women with stress incontinence and overactive bladder syndrome.~In the 3 groups of patients the subjects will be randomized to either active treatment or placebo treatment. The placebo treatment will be done with a vibration device with an amplitude of 0 mm. Subjects will be randomized by a draw.
Study NCT03277755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335 800 mg
Description: Participants will receive AL-335 800 mg (2 tablets of 400 mg AL-335) single oral dose on Day 1 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
Study NCT03519347 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point of Care Testing
Description: POC testing will use the Abbott BLUE I-STAT CHEM8+ , a portable, handheld device that provides lab quality analysis within 2-3 minutes using a few drops of whole blood (≤100uL).
Study NCT03519347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Monitor
Description: Device is one-third of the size of a triple-A battery and is placed subcutaneously in the left chest during a brief procedure that can be done in-office under local anesthesia.
Study NCT03741660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: konjac glucomannan
Description: Konjac-mannan fiber-enriched biscuits (0.7 g/412KJ \[100kcal\] of glucommanan)
Study NCT03741660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: wheat bran
Description: Wheat bran (hard red wheat bran) fiber enriched biscuits
Study NCT01680718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
Study NCT01680718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
Study NCT01680718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).
Study NCT00378209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given intravenously on days 1,4,8 and 11 of a 21-day cycle for a minimum of 8 cycles.
Study NCT00378209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Taken orally once a day for 2 weeks (days 1-14) of a 21-day cycle for a minimum of 8 cycles